

WHAT IS CLAIMED IS:

1. A method of combination therapy for treatment of a subject diagnosed as having Fabry disease comprising administering a therapeutically effective amount of a combination therapy selected from two or more of an enzyme replacement therapy, gene therapy, and a small molecule therapy.
2. The method according to claim 1 wherein the combination therapy comprises alternating between administration of an enzyme replacement therapy and a small molecule therapy.
3. The method according to claim 1 wherein the combination therapy comprises simultaneously administering an enzyme replacement therapy and a small molecule therapy.
4. The method according to claim 1 wherein the combination therapy comprises gene therapy and a therapy selected from the group consisting of enzyme replacement therapy and small molecule therapy.
5. The method according to claim 1 wherein the combination therapy produces a diminution in globotriaosylceramide.
6. The method according to claim 1 wherein the enzyme replacement therapy provides an effective amount of  $\alpha$ -galactosidase A.
7. The method according to claim 1 wherein the small molecule therapy comprises administering to the subject an effective amount of deoxynojirimycin or a deoxynojirimycin derivative.
8. The method according to claim 7, wherein the deoxynojirimycin derivative is *N*-butyldeoxynojirimycin (NB-DNJ) or *N*-(5-adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNJ).
9. The method according to claim 1, wherein the small molecule therapy comprises administering to the subject an effective amount of a *D*-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4) derivative.

10. The method according to claim 9, wherein the P4 derivative is D-*threo*-1-(3',4'-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (D-t-et-P4).
11. The method according to 1, wherein Fabry disease has at least one central nervous system manifestation and the small molecule therapy comprises AMP-DNJ.